Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing life-transforming therapeutics for people living with genetically driven diseases, today ...

Neuropathy, skin rash, and hyperglycemia following enfortumab vedotin treatment were associated with improved PFS in ...

The federal government has long sought to prevent the horrors of drug addiction by interdicting the supply of dangerous ...

Oregon voters approved a first-of-its-kind law to decriminalize all hard drugs. But after three disastrous years, the state ...

Authors Table of Contents Media Contact For general and media inquiries and to book our experts, please contact: ...

A new initiative includes $600,000 in state funds to begin Narcan training sessions available to the public across the Bronx ...

The public is invited to participate in an islandwide sign-waving event Friday to raise awareness about drug overdoses, ...

Vertigo Releasing has released a poster and trailer for Sew Torn, the neo-noir crime thriller from director Freddy MacDonald. The film follows Barbara (Eve Connolly), a seamstress who finds herself ...

The billboards have been seen in Andersonstown as well as other areas of Belfast.

It’s been three months since California voters overwhelmingly approved Proposition 36, a new law that pledged to provide ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...